San Diego-based biopharmaceutical company ADVENTRX Pharmaceuticals announced today that its previously announced corporate name change has now gone into effect. The company’s name has now officially been changed to “Mast Therapeutics, Inc.” Effective at the opening of trading today, the company’s new ticker symbol is “MSTX.” Mast Therapeutics’ stock is listed on the NYSE MKT.
Mast Therapeutics’ lead product candidate will be hereafter referred to as “MST-188” (formerly ANX-188). Additionally, a new CUSIP number, 576314 108, has been assigned to the company’s common stock.
Outstanding stock certificates and warrants for shares of the company’s common stock have not been affected by the name change, and they will continue to be valid and do not need to be exchanged.
Mast Therapeutics is a publicly traded biopharmaceutical company engaged in leveraging its MAST (Molecular Adhesion and Sealant Technology) platform – which has resulted from more than 20 years of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers – in the development of MST-188, the company’s lead product candidate. MST-188 has been created to address serious or life-threatening diseases of significant unmet need and is a cytoprotective, hemorheologic, anti-inflammatory, and anti-thrombotic agent with potential utility in diseases or conditions that are characterized by microcirculatory insufficiency (endothelial dysfunction and/or impaired blood flow). Mast Therapeutics is headquartered in San Diego, Calif.
Mast Therapeutics is currently recruiting subjects in EPIC, its pivotal Phase 3 study of MST-188 in sickle cell disease. A Phase 2 clinical study of MST-188 in acute limb ischemia – a complication of peripheral arterial disease – is planned for late 2013 or early 2014.
For more information, visit www.masttherapeutics.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
